StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Ibrance (palbociclib by Quarter

Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Ibrance (palbociclib: $1,058M in Q2 2026, up 0.9% from a year earlier.

Latest, Q2 2026
1,058
Period ended Jun 28, 2026
Change on a year earlier
+0.9%
1,049 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
35
Documents cited below

Where the Q2 2026 figure comes from

“|| Ibrance | 1,058 | 1,049 | 1% | — | 707 | 696 | 2% | 351 | 353 | (1%) | (4%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIbrance (palbociclib — HR+/HER2- metastatic breast cancer) — Worldwide revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 20261,058+0.9%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 20261,008+3.2%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 20251,040-5.0%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 20251,057-2.8%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 20251,049-7.2%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025977-7.3%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 20241,095-2.1%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 20241,087-12.6%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 20241,130-9.4%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 20241,054-7.9%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 20231,118-12.6%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 20231,244-3.0%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 20231,247-5.5%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 20231,144-7.5%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 20221,279-8.5%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 20221,283-7.1%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗

Breakdown

What makes up ibrance (palbociclib

Cite this data

StockData. (2026). Pfizer Ibrance (palbociclib ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/ibrance-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.